Cargando…
Association of germline TYK2 variation with lung cancer and non‐Hodgkin lymphoma risk
Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate‐to‐severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibit...
Autores principales: | Yarmolinsky, James, Amos, Christopher I., Hung, Rayjean J., Moreno, Victor, Burrows, Kimberley, Smith‐Byrne, Karl, Atkins, Joshua R., Brennan, Paul, McKay, James D., Martin, Richard M., Davey Smith, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588593/ https://www.ncbi.nlm.nih.gov/pubmed/35747941 http://dx.doi.org/10.1002/ijc.34180 |
Ejemplares similares
-
Mendelian randomisation analysis of circulating adipokines and C‐reactive protein on breast cancer risk
por: Robinson, Timothy, et al.
Publicado: (2020) -
Insecticide use and risk of non‐Hodgkin lymphoma subtypes: A subset meta‐analysis of the North American Pooled Project
por: Kachuri, Linda, et al.
Publicado: (2020) -
Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms
por: Willett, E V, et al.
Publicado: (2005) -
Long‐term hospitalisation rates among 5‐year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study
por: Rugbjerg, Kathrine, et al.
Publicado: (2017) -
Common genetic variations in telomere length genes and lung cancer: a Mendelian randomisation study and its novel application in lung tumour transcriptome
por: Cortez Cardoso Penha, Ricardo, et al.
Publicado: (2023)